Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,016
  • Shares Outstanding, K 59,517
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,150 K
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.72
Trade CLBS with:

Options Overview Details

View History
  • Implied Volatility 138.02%
  • Historical Volatility 27.74%
  • IV Percentile 40%
  • IV Rank 31.97%
  • IV High 350.79% on 10/30/20
  • IV Low 38.03% on 09/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 26
  • Volume Avg (30-Day) 105
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 4,893
  • Open Int (30-Day) 9,690

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate -0.10
  • Low Estimate -0.13
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +58.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1600 +1.72%
on 09/20/21
1.3400 -11.94%
on 09/01/21
-0.1200 (-9.23%)
since 08/27/21
3-Month
1.1500 +2.61%
on 08/20/21
1.6400 -28.05%
on 06/29/21
-0.4600 (-28.05%)
since 06/28/21
52-Week
1.1500 +2.61%
on 08/20/21
4.8900 -75.87%
on 01/20/21
-0.6000 (-33.71%)
since 09/28/20

Most Recent Stories

More News
Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.1800 (-2.48%)
Caladrius Biosciences, Inc. (CLBS) Reports Q2 Loss, Misses Revenue Estimates

Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of 33.33% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

CLBS : 1.1800 (-2.48%)
Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides...

CLBS : 1.1800 (-2.48%)
Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.1800 (-2.48%)
Caladrius Biosciences to Present at Zooming with LD

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.1800 (-2.48%)
Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.1800 (-2.48%)
Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.1800 (-2.48%)
Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.1800 (-2.48%)
New Strong Sell Stocks for May 27th

AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021

LLY : 221.60 (-2.12%)
EKSO : 4.40 (-4.35%)
CLBS : 1.1800 (-2.48%)
AFYA : 18.60 (-7.32%)
BNL : 24.97 (+0.04%)
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.1800 (-2.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve...

See More

Key Turning Points

3rd Resistance Point 1.2363
2nd Resistance Point 1.2251
1st Resistance Point 1.2025
Last Price 1.1800
1st Support Level 1.1687
2nd Support Level 1.1575
3rd Support Level 1.1349

See More

52-Week High 4.8900
Fibonacci 61.8% 3.4613
Fibonacci 50% 3.0200
Fibonacci 38.2% 2.5787
Last Price 1.1800
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar